In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release

Journal of Biomedical Materials Research - Part A

Volumn 100 A, Issue 8, 2012, Pages 2106-2118

  Baldwin, Aaron D ^a   Robinson, Karyn G ^b   Militar, Jaimee L ^b   Derby, Christopher D ^b   Kiick, Kristi L ^a,c   Akins Jr , Robert E ^a,b  

^a DUPONT COMPANY   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

Author keywords

anticoagulant; controlled release; heparin; hydrogel

Indexed keywords

ANTICOAGULANT; ANTICOAGULATION THERAPY; BURST RELEASE; COAGULATION TIME; CONTROLLED RELEASE; CROSS-LINKABLE; CROSS-LINKED HYDROGELS; CROSSLINKED; DELIVERY METHODS; FIRST ORDER KINETICS; HEPARIN; IN-SITU; LONG LASTING; LOW-MOLECULAR WEIGHT HEPARINS; MALEIMIDE GROUP; NEW ZEALAND WHITE RABBIT; PEDIATRIC PATIENTS; PLASMA SAMPLES; POLY(ETHYLENE GLYCOL) HYDROGEL;

COAGULATION; POLYETHYLENE GLYCOLS; POLYSACCHARIDES;

HYDROGELS;

CHROMOGENIC SUBSTRATE; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; MALEIMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG HYDROLYSIS; FEASIBILITY STUDY; HYDROGEL; IN SITU HYBRIDIZATION; NONHUMAN; PLASMA; PROTEIN HYDROLYSIS; SUSTAINED DRUG RELEASE;

ANIMALS; ANTICOAGULANTS; AREA UNDER CURVE; CROSS-LINKING REAGENTS; DELAYED-ACTION PREPARATIONS; HEPARIN, LOW-MOLECULAR-WEIGHT; HYDROGELS; HYDROLYSIS; KINETICS; POLYETHYLENE GLYCOLS; PROSTHESIS IMPLANTATION; RABBITS; RHEOLOGY; TIME FACTORS;

EID: 84862756102     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34050     Document Type: Article

References (75)

1. Mackay J, Mensah GA, Mendis S, Greenlund K, World Health Organization, NetLibrary Inc. The Atlas of Heart Disease and Stroke. Geneva: World Health Organization; 2004. p 112.
2. Mathers CD, Loncar D,. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: 2011-2030.
3. Mackman N,. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-918.
4. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE,. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
5. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E,. The pharmacology and management of the vitamin K antagonists. Chest 2004; 126: 204S-233S.
6. Di Nisio M, Middeldorp S, Büller HR,. Direct Thrombin inhibitors. N Engl J Med 2005; 353: 1028-1040.
7. Weitz JI, Crowther M,. Direct thrombin inhibitors. Thromb Res 2002; 106: V275-V284.
8. O'Brien PJ, Mureebe L,. Direct thrombin inhibitors. J Cardiovas Pharmacol Ther 2011; Epub ahead of print, Feb 18.
9. Eriksson BI, Quinlan DJ, Weitz JI,. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1-22.
10. Turpie AGG,. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007; 27: 1238-1247.
11. Hedenius PER, Wilander O,. The influence of intravenous injections of heparin in man on the time of coagulation.1. Acta Med Scand 1936; 88: 443-449.
12. Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J,. A comparison of the anti thrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 1984; 35: 613-625.
13. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM,. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28: 609-618.
14. Handeland GF, Abildgaard U, Holm HA, Arnesen KE,. Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39: 107-112.
15. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-687.
16. Arbit E, Goldberg M, Gomez-Orellana I, Majuru S,. Oral heparin: Status review. Thromb J 2006; 4: 6.
17. Homar M, Cegnar M, Kotnik M, Peternel L,. Toward effective long-term prevention of thromboembolism: Novel oral anticoagulant delivery systems. Semin Thromb Hemost 2010; 31: 113-122.
18. Baughman RA, Kapoor SC, Agarwal RK, Kisicki J, Catella-Lawson F, FitzGerald GA,. Oral delivery of anticoagulant doses of heparin: A randomized, double-blind, controlled study in humans. Circulation 1998; 98: 1610-1615.
19. Rivera TM, Leone-Bay A, Paton DR, Leipold HR, Baughman RA,. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: Pharmacological considerations. Pharm Res 1997; 14: 1830-1834.
20. Majuru S,. Advances in the oral delivery of heparin from solid dosage forms using Emisphere's eligen oral drug delivery technology. Drug Deliv Technol 2004; 4: 84-89.
21. Mousa SA, Zhang F, Aljada A, Chaturvedi S, Takieddin M, Zhang H, Chi L, Castelli MC, Friedman K, Goldberg MM, et al. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. J Clin Pharmacol 2007; 47: 1508-1520.
22. Leone-Bay A, Paton DR, Variano B, Leipold H, Rivera T, Miura-Fraboni J, Baughman RA, Santiago N,. Acylated non-[alpha]-amino acids as novel agents for the oral delivery of heparin sodium, USP. J Control Release 1998; 50: 41-49.
23. Park JW, Jeon OC, Kim SK, Al-Hilal TA, Moon HT, Kim CY, Byun Y,. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative. Mol Pharm 2010; 7: 836-843.
24. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, Maincent P,. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002; 105: 230-235.
25. Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N,. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release 2006; 113: 38-42.
26. Hayes PY, Ross BP, Thomas BG, Toth I,. Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin. Bioorg Med Chem 2006; 14: 143-152.
27. Dal Pozzo A, Acquasaliente M, Geron MR, Andriuoli G,. New heparin complexes active by intestinal absorption. I. Multiple ion pairs with basic organic compounds. Thromb Res 1989; 56: 119-124.
28. Spahn G,. Compliance with self-administration of heparin injections in outpatients. Eur J Trauma 2002; 28: 104-109.
29. Weitz JI, Linkins L-A,. Beyond heparin and warfarin: The new generation of anticoagulants. Exp Opin Invest Drugs 2007; 16: 271-282.
30. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM,. Polymeric systems for controlled drug release. Chem Rev (Washington, DC, US) 1999; 99: 3181-3198.
31. Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P, Michelson AD,. Antithrombotic therapy in neonates and children. Chest 2008; 133: 887S-968S.
32. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L,. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
33. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen D, Powers P,. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172.
34. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G,. Pharmacology and management of the vitamin K antagonists. Chest 2008; 133: 160S-198S.
35. White RH, Zhou H, Romano P, Mungall D,. Changes in plasma warfarin levels and variations in steady-state prothrombin times. Clin Pharmacol Ther 1995; 58: 588-593.
36. Hoffman AS,. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002; 54: 3-12.
37. Baldwin AD, Kiick KL,. Polysaccharide-modified synthetic polymeric biomaterials. Peptide Sci 2010; 94: 128-140.
38. Nie T, Baldwin A, Yamaguchi N, Kiick KL,. Production of heparin-functionalized hydrogels for the development of responsive and controlled growth factor delivery systems. J Control Release 2007; 122: 287-296.
39. Tae G, Scatena M, Stayton PS, Hoffman AS,. PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor. J Biomater Sci Polym Ed 2006; 17: 187-197.
40. Cai S, Liu Y, Zheng Shu X, Prestwich GD,. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 2005; 26: 6054-6067.
41. Gutowska A, Bae YH, Feijen J, Kim SW,. Heparin release from thermosensitive hydrogels. J Control Release 1992; 22: 95-104.
42. Vasudev SC, Chandy T, Sharma CP,. Development of chitosan/polyethylene vinyl acetate co-matrix: Controlled release of aspirin-heparin for preventing cardiovascular thrombosis. Biomaterials 1997; 18: 375-381.
43. Brazel CS, Peppas NA,. Pulsatile local delivery of thrombolytic and antithrombotic agents using poly(N-isopropylacrylamide-co-methacrylic acid) hydrogels. J Control Release 1996; 39: 57-64.
44. Hermanson GT,. Bioconjugate Techniques. San Diego, California: Academic Press; 2008. 1202 p.
45. Macintosh FC,. A colorimetric method for the standardization of heparin preparations. Biochem J. 1941; 35: 776-782.
46. Raad I, Hachem R, Tcholakian RK, Sherertz R,. Efficacy of minocycline and EDTA lock solution in preventing catheter-related bacteremia, septic phlebitis, and endocarditis in rabbits. Antimicrob Agents Chemother 2002; 46: 327-332.
47. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan B-BC,. Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer. Drug Dev Res 2006; 67: 166-174.
48. Osmond RIW, Kett WC, Skett SE, Coombe DR,. Protein-heparin interactions measured by BIAcore 2000 are affected by the method of heparin immobilization. Anal Biochem 2002; 310: 199-207.
49. Young JJ, Cheng KM, Tsou TL, Liu HW, Wang HJ,. Preparation of cross-linked hyaluronic acid film using 2-chloro-1-methylpyridinium iodide or water-soluble 1-ethyl-(3,3-dimethylaminopropyl)carbodiimide. J Biomater Sci Polym Ed 2004; 15: 767-780.
50. Yu L, Ding J,. Injectable hydrogels as unique biomedical materials. Chem Soc Rev 2008; 37: 1473-1481.
51. Schelté P, Boeckler C, Frisch B, Schuber F,. Differential reactivity of maleimide and bromoacetyl functions with thiols: Application to the preparation of liposomal diepitope constructs. Bioconjug Chem 1999; 11: 118-123.
52. Lutolf MP, Hubbell JA,. Synthesis and physicochemical characterization of end-linked poly(ethylene glycol)-co-peptide hydrogels formed by Michael-type addition. Biomacromolecules 2003; 4: 713-722.
53. Zheng Shu X, Liu Y, Palumbo FS, Luo Y, Prestwich GD,. In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 2004; 25: 1339-1348.
54. Hiemstra C, van der Aa LJ, Zhong Z, Dijkstra PJ, Feijen J,. Novel in situ forming, degradable dextran hydrogels by Michael addition chemistry: Synthesis, rheology, and degradation. Macromolecules 2007; 40: 1165-1173.
55. Latridis JC, Wu J, Yandow JA, Langevin HM,. Subcutaneous tissue mechanical behavior is linear and viscoelastic under uniaxial tension. Connective Tissue Res 2003; 44: 208-217.
56. Rydholm AE, Anseth KS, Bowman CN,. Effects of neighboring sulfides and pH on ester hydrolysis in thiol-acrylate photopolymers. Acta Biomater 2007; 3: 449-455.
57. Reddy SK, Anseth KS, Bowman CN,. Modeling of network degradation in mixed step-chain growth polymerizations. Polymer 2005; 46: 4212-4222.
58. Rydholm AE, Reddy SK, Anseth KS, Bowman CN,. Controlling network structure in degradable thiol-acrylate biomaterials to tune mass loss behavior. Biomacromolecules 2006; 7: 2827-2836.
59. Bisio A, Vecchietti D, Citterio L, Guerrini M, Raman R, Bertini S, Eisele G, Naggi A, Sasisekharan R, Torri G,. Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thromb Haemost 2009; 102: 865-873.
60. Bourne DW,. Pharmacokinetics. In:, Banker GS, Rhodes CT, editors. Modern Pharmaceutics. New York: Marcel Dekker Inc.; 2002. p 838.
61. Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J,. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: Implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 2008; 34: 074-085.
62. Tamada JA, Langer R,. Erosion kinetics of hydrolytically degradable polymers. Proc Natl Acad Sci 1993; 90: 552-556.
63. Schoenmakers RG, van de Wetering P, Elbert DL, Hubbell JA,. The effect of the linker on the hydrolysis rate of drug-linked ester bonds. J Control Release 2004; 95: 291-300.
64. BlatnAü J, Fiamoli V,. Treatment of deep vein thrombosis with continuous intravenous infusion of LMWH in childrena - An alternative to subcutaneous application when needed. Vnitr ní lékar ství 2009; 55: 227-232.
65. Fiamoli V, BlatnAü J, Zapletal O, Kohlerova S, Janousova E,. Treatment of deep vein thrombosis with continuous IV infusion of LMWH: A retrospective study in 32 children. Thrombosis 2011; Article ID 981497:1-4.
66. Hommes DW, Bura A, Mazzolai L, Büller HR, ten Cate JW,. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992; 116: 279-284.
67. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1114.
68. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982.
69. Prandoni P, Carta M, Cogo A, Ruol A, Vigo M, Casara D, Lensing AWA, Büller HR, ten Cate JW,. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. The Lancet 1992; 339: 441-445.
70. Monte AA, Bodmer M, Schaeffer TH,. Low-molecular-weight heparin overdose: Management by observation. Ann Pharmacother 2010; 44: 1836-1839.
71. Ngo A, Tan D, Olson K,. Low molecular weight heparin overdose. Ann Emerg Med 2008; 51: 488-489.
72. Romagnoli F, Banfi R, Cinaglia I, Balloni L, Paciello A,. A massive overdose of the low molecular weight heparin, parnaparin: A case report. Eur J Hospital Pharmacy Practice 2007; 13: 32-33.
73. Carr JA, Silverman N,. The heparin-protamine interaction. A review. J Cardiovasc Surg 1999; 40: 659-666.
74. Levy JH, Cormack JG, Morales A,. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg 1995; 81: 35-37.
75. Veronese FM, Pasut G,. PEGylation, successful approach to drug delivery. Drug Discov Today 2005; 10: 1451-1458.